Skip to main content

Partnering with Biopharma

From discovery through commercialization, Foundation Medicine provides biopharma companies with actionable insights into the oncogenomics of both rare and common cancers.

Working to Meet Your Needs and Challenges

Foundation Medicine is your dedicated partner to support your therapeutic development from discovery through to commercialization. Our innovations include proven comprehensive genomic profiling tests, genomic data solutions, clinical trial solutions, and companion diagnostic development/commercialization. We can help stratify patient cohorts, inform clinical trial design and drug development decisions, and increase patient access to potential investigational agents and trials.

Biopharmaceutical Solutions

Genomic Data Solutions

Our genomic information knowledgebase is continuously evolving, informed by every clinical sample sequenced with Foundation Medicine’s comprehensive genomic profiling tests. You can also access a unique clinicogenomic data set through our partnership with Flatiron Health, a leading provider of clinical data.

Genomic Data Solutions

Clinical Trial Solutions

We help accelerate biomarker-driven clinical trials through better design, planning, and enrollment. We have a portfolio of assays available for use to enroll patients in clinical trials, including FDA-approved FoundationOne®CDx and FoundationOne®Liquid CDx, and can support regulatory aspects of study start-up such as Study Risk Determinations (SRDs) and Investigational Device Exemptions (IDEs).

Clinical Trial Solutions

Companion Diagnostic (CDx) Development & Commercialization

Leveraging a proven portfolio and established platform may help: accelerate CDx development; mitigate development, regulatory, and commercial risk; and drive commercial adoption.

CDx Development & Commercialization

Biopharma Stats

>400k

patients profiled (FoundationCore)

>50k

clinico-genomic profiles (CGDB)

>50

biopharma partners

Need More Details?

Our client services team is here to help, Monday through Friday 8AM – 8PM EST. 

Contact Us

Important Safety Information

Select

FoundationOne CDx

FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com.  

FoundationOne Liquid CDx

FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration.  Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible.  For the complete label, including companion diagnostic indications and complete risk information, please visit  www.F1LCDxLabel.com.